U.S. Markets open in 45 mins

Tobacco Company Imperial Brands, Auxly Cannabis Close On Partnership, $92.8M Investment

Nina Zdinjak

Auxly Cannabis Group Inc. (OTC: CBWTFannounced Wednesday the closing of a transaction with Imperial Tobacco Group plc (OTC: IMBBY).

As previously announced in July, Imperial Brands invested CA$123 million ($92.8 million) in Auxly by way of a debenture that is convertible into 19.9% ownership of the cannabis company. 

Imperial is providing Auxly with global licenses to its vaping technology and access to its vapor innovation business, and will make Auxly its exclusive partner for its cannabis business operations, according to Wednesday's announcement. 

“We are delighted to announce the closing of this transaction to formally mark the start of our strategic partnership with Imperial Brands,” Auxly CEO Hugo Alves said in a statement.

“We believe there is considerable opportunity for growth and value creation for both companies. We are looking forward to working with the incredibly strong team at Imperial Brands as we prepare to launch our portfolio of branded derivative products, formulated and manufactured at our subsidiary, Dosecann, later this year. “

 Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.

Auxly is appointing Imperial's Conrad Tate to its board as a director and John Downing as a non-voting observer. 

“I’m thrilled to be closing this transaction with Auxly, a dynamic, highly skilled organization that has all the ingredients required for delivering success in the branded derivatives market and beyond,” Tate, Imperial Brands' new corporate development director, said in a statement.

“We’re excited by the opportunities this partnership offers and look forward to working with Auxly to build its business and realize its significant future growth potential.”

Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.

Photo courtesy of Imperial Brands. 

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.